Philis-Tsimikas, AthenaBillings, Liana KBusch, RobertPortillo, Cristobal MoralesSahay, RakeshHalladin, NatalieEggert, SarahBegtrup, KamillaHarris, Stewart2023-01-252023-01-252019-04-04http://hdl.handle.net/10668/13562To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. In this 26-week, phase IIIb, open-label, parallel-group, treat-to-target trial, conducted at 74 sites in 11 countries, insulin-naïve people aged ≥18 years with glycated haemoglobin (HbA1c) 53-97 mmol/mol (7.0-11.0%), body mass index 20-40 kg/m2 and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor ± oral antidiabetic drugs were randomized 1:1 to once-daily IDegLira or IGlar U100, both as add-on to existing therapy. The primary endpoint was change in HbA1c from baseline to week 26. A total of 210 participants were randomized to each treatment arm. Mean HbA1c reductions were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100; confirming non-inferiority (P  The favourable safety and efficacy profile of IDegLira in people with uncontrolled T2D on SGLT2 inhibitors, and lower weight gain and hypoglycaemia risk versus IGlar U100, suggest that clinicians should consider IDegLira initiation in this population.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/GLP-1 analogueSGLT2 inhibitorinsulin therapyliraglutiderandomized trialtype 2 diabetesAgedDiabetes Mellitus, Type 2Drug-Related Side Effects and Adverse ReactionsFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulin, Long-ActingLiraglutideMaleMiddle AgedSodium-Glucose Transporter 2 Inhibitorsresearch article30761720open access10.1111/dom.136661463-1326PMC6593861https://doi.org/10.1111/dom.13666https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593861/pdf